Phase I study using Vidaza (5'-azacytidine) as a DNA methylation inhibitor in patients with chronic lymphocytic leukemia

Trial Profile

Phase I study using Vidaza (5'-azacytidine) as a DNA methylation inhibitor in patients with chronic lymphocytic leukemia

Not stated
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2007

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top